KR101071851B1 - A Process for Preparing an Extract of Black Ginseng with Increased Rg3 and Rh2 Contents - Google Patents
A Process for Preparing an Extract of Black Ginseng with Increased Rg3 and Rh2 Contents Download PDFInfo
- Publication number
- KR101071851B1 KR101071851B1 KR1020090017259A KR20090017259A KR101071851B1 KR 101071851 B1 KR101071851 B1 KR 101071851B1 KR 1020090017259 A KR1020090017259 A KR 1020090017259A KR 20090017259 A KR20090017259 A KR 20090017259A KR 101071851 B1 KR101071851 B1 KR 101071851B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- black ginseng
- steaming
- black
- content
- Prior art date
Links
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 185
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 185
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 185
- 230000001965 increasing effect Effects 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 241000208340 Araliaceae Species 0.000 title claims abstract 14
- 239000000284 extract Substances 0.000 title description 2
- 238000010025 steaming Methods 0.000 claims abstract description 91
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 60
- 230000001093 anti-cancer Effects 0.000 abstract description 43
- 229930182490 saponin Natural products 0.000 abstract description 29
- 150000007949 saponins Chemical class 0.000 abstract description 29
- 235000017709 saponins Nutrition 0.000 abstract description 29
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 22
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 240000004371 Panax ginseng Species 0.000 description 171
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 32
- 230000008569 process Effects 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 19
- 201000005202 lung cancer Diseases 0.000 description 19
- 208000020816 lung neoplasm Diseases 0.000 description 19
- 235000002789 Panax ginseng Nutrition 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 208000001382 Experimental Melanoma Diseases 0.000 description 7
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 235000012149 noodles Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 241000234282 Allium Species 0.000 description 3
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 3
- 240000002234 Allium sativum Species 0.000 description 3
- 235000002566 Capsicum Nutrition 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000006002 Pepper Substances 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 235000016761 Piper aduncum Nutrition 0.000 description 3
- 240000003889 Piper guineense Species 0.000 description 3
- 235000017804 Piper guineense Nutrition 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000004611 garlic Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 244000236458 Panicum colonum Species 0.000 description 1
- 235000015225 Panicum colonum Nutrition 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 229910000004 White lead Inorganic materials 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- -1 cancer prevention Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 인삼을 상압 및 고압의 조건으로 반복 증숙하여 제조된 항암활성을 갖는 인삼사포닌 성분인 Rg3 및 Rh2의 함량이 증진된 흑삼 및 그의 제조방법에 관한 것이다. 본 발명의 Rg3 및 Rh2의 함량이 증가된 흑삼의 제조방법은 건조된 인삼을 90 내지 110℃에서 1 내지 3시간동안 증숙한 다음, 50 내지 70℃에서 1 내지 3시간 동안 건조시키는 공정을 9회 반복수행하여 흑삼을 제조하는 방법에 있어서, 제 1회 및 제 6회차 증숙공정을 5 내지 15기압의 압력하에서 수행하는 것을 특징으로 한다. 본 발명의 제조방법을 이용할 경우, 항암효과를 나타내는 인삼사포닌 성분인 Rg3와 Rh2의 함량이 증가된 흑삼 흑삼 추출물을 제조할 수 있으므로, 항암치료제 및 항암 건강기능식품의 개발에 널리 활용될 수 있을 것이다.The present invention relates to a black ginseng and a method for producing the same, the content of Rg3 and Rh2 which is a ginseng saponin component having anticancer activity prepared by repeated steaming ginseng under the conditions of normal pressure and high pressure. In the method for producing black ginseng with increased contents of Rg3 and Rh2 of the present invention, the dried ginseng is steamed at 90 to 110 ° C. for 1 to 3 hours and then dried at 50 to 70 ° C. for 1 to 3 hours. In the method for repeatedly producing black ginseng, the first and sixth steaming steps are performed under a pressure of 5 to 15 atmospheres. When using the production method of the present invention, black ginseng black ginseng extract with increased content of Rg3 and Rh2, which are anti-cancer effect ginseng saponins, can be prepared, and thus will be widely used for the development of anticancer drugs and anti-cancer health foods. .
흑삼, 흑삼 추출물, 고압, 증숙, Rg3, Rh2, 항암치료제, 항암 건강기능식품 Black ginseng, black ginseng extract, high pressure, steaming, Rg3, Rh2, anticancer drug, anticancer health food
Description
본 발명은 Rg3 및 Rh2의 함량이 증가된 흑삼 및 그의 제조방법에 관한 것이다. 좀 더 구체적으로, 본 발명은 인삼을 상압 및 고압의 조건으로 반복 증숙하여 제조된 항암활성을 갖는 인삼사포닌 성분인 Rg3 및 Rh2의 함량이 증진된 흑삼 및 그의 제조방법에 관한 것이다.The present invention relates to a black ginseng having an increased content of Rg3 and Rh2 and a method for producing the same. More specifically, the present invention relates to black ginseng and a method for producing the same, the content of Rg3 and Rh2, which is a ginseng saponin component having anticancer activity, prepared by repeated steaming ginseng under normal and high pressure conditions.
인삼은 이미 오래전부터 그 효능 및 유효성이 잘 알려져 온 한약재이다. 상기 인삼은 수삼(水蔘, fresh ginseng)을 그대로 사용하거나, 건조시켜 백삼(白蔘, white ginseng)의 형태로 제조하여 사용하거나 또는 증숙시켜서 홍삼(紅蔘, red ginseng)의 형태로 제조하여 사용되었다. Ginseng is a herbal medicine that has long been known for its efficacy and effectiveness. The ginseng is used as it is, ginseng (水 蔘, fresh ginseng), or dried and prepared in the form of white ginseng (白 蔘, white ginseng) or steamed red ginseng (紅 蔘, red ginseng) used in the form of It became.
한편, 인삼의 가공방법에 따라 인삼에 존재하지 않는 새로운 성분이 생성되며, 인삼에 비해서 항산화작용을 비롯한 여러가지 생리활성에 대해서 보다 우수한 효과를 나타내는 새로운 가공 인삼을 개발할 수 있다(참조: Okamura N., et al., Biol. Pharm. Bull., 17(2), p.270, 1994). 특히, 약 1,000년 전부터 제조되어 온 것으로 알려진 홍삼은 증숙공정을 거치는 동안 2차적 성분변환이 일어나 수삼이나 백삼에 존재하지 않는 홍삼 특유의 새로운 약효성분들이 생성되기도 하고, 어떤 활성성분은 함량 증가가 일어난다. On the other hand, according to the processing method of ginseng, a new ingredient that does not exist in the ginseng is produced, it is possible to develop a new processed ginseng that has a superior effect on various physiological activities including antioxidant activity compared to ginseng (Okamura N., et al., Biol. Pharm. Bull., 17 (2), p. 270, 1994). In particular, red ginseng, which has been known to have been manufactured for about 1,000 years, undergoes secondary conversion during the steaming process, resulting in new active ingredients unique to red ginseng or red ginseng. .
지금까지 연구된 바에 의하면, 인삼에 존재하는 활성성분은 대체로 인삼사포닌(ginsenoside)이라고 알려져 있는데, 인삼사포닌은 트리터펜(triterpene)인 비당부(protopanaxadiol 또는 protopanaxatriol)의 R1, R2, R3의 알콜성 OH기에 글루코스, 람노스, 자일로스, 아라비노스와 같은 당류가 에스테르 결합된 구조를 갖는 화합물로서, 현재까지 30종 이상이 밝혀져 있으며, 항암작용, 항당뇨작용, 중추신경 억제작용, 동맥경화 및 고혈압의 예방, 간기능 촉진 및 숙취제거 효과, 항피로 및 항스트레스 작용, 항산화작용, 항염활성, 단백질합성 촉진작용, 면역증강작용 등의 약리활성 효과를 나타내는 것으로 알려져 있다. According to the research so far, the active ingredient in ginseng is known as ginseng saponin (ginsenoside), which is an alcoholic OH of R1, R2 and R3 of triterpene (protopanaxadiol or protopanaxatriol). As a compound having a structure in which sugars such as glucose, rhamnose, xylose and arabinose are ester-bonded to the group, more than 30 species have been identified to date, and have anticancer activity, antidiabetic action, central nerve suppression effect, arteriosclerosis and hypertension. It is known to exhibit pharmacological activity effects such as prevention, liver function and hangover removal effect, anti-fatigue and anti-stress action, antioxidant activity, anti-inflammatory activity, protein synthesis promoting action, immune enhancing effect.
이들 인삼사포닌은 대체로 수삼에 존재하는 것으로 알려져 있으나, 특정한 일부 인삼사포닌은 가공된 인삼에만 존재하는 것으로 알려져 있다(참조: Hideyuki Nakata, et al., Cancer Science, 89(7): 733-740, 2005; Y.K. Yue, et al., Biochemical Pharmacology, 72(4): 437-445, 2006). 예를 들면, 인삼사포닌 중에서 Rg2, Rg3, Rh1, Rh2 등은 수삼에는 존재하지 않으나, 수삼을 증숙 및 건조시켜 제조된 가공된 인삼의 일종인 홍삼에는 존재하는 것으로 알려져 있다. 이처럼 가공된 인삼에만 존재하는 인삼사포닌은 암예방작용, 암세포성장 억제작용, 혈압강하 작용, 뇌신경세포 보호작용, 항혈전작용, 항산화작용 등의 약리활성 효과가 다른 인삼사포닌 보다도 우수하다는 연구결과가 보고되고 있어, 이들 가공된 인삼에만 존재하는 인삼사포닌에 대한 연구가 활발하게 진행되고 있다.These ginseng saponins are generally known to exist in fresh ginseng, but some specific ginseng saponins are known to exist only in processed ginseng. Hideyuki Nakata, et al., Cancer Science, 89 (7): 733-740, 2005 YK Yue, et al., Biochemical Pharmacology, 72 (4): 437-445, 2006). For example, Rg2, Rg3, Rh1, Rh2 and the like are not present in ginseng saponins, but are known to exist in red ginseng, a processed ginseng produced by steaming and drying ginseng. Ginseng saponins present in the processed ginseng are superior to other ginseng saponins than other ginseng saponins such as cancer prevention, cancer cell growth inhibition, blood pressure lowering, neuroprotective neuroprotection, antithrombotic action and antioxidant activity. The research on the ginseng saponin which exists only in these processed ginseng is actively progressing.
최근에는, 이들 가공된 인삼에만 존재하는 인삼사포닌의 함량을 더욱 높이기 위한 많은 연구가 진행되었으며, 그 결과 태극삼(太極參, taeguk ginseng), 흑삼(黑參, black ginseng) 등의 가공인삼이 개발되었다. 특히, 흑삼은 수회 증숙 및 건조과정을 거쳐 인삼이 검은 색으로 변한 삼을 의미하는 것으로서, 수회 증식 및 건조과정을 거치면서 기본적으로 존재하는 인삼사포닌이 소실되지 않을 뿐만 아니라, 가공된 인삼에만 존재하는 인삼사포닌의 함량이 증진되는 것으로 알려져 있어, 이러한 흑삼을 보다 효과적으로 제조하는 방법에 대한 연구가 활발하게 수행되고 있다.Recently, many studies have been conducted to further increase the content of ginseng saponin present only in these processed ginseng, and as a result, processed ginseng such as taeguk ginseng and black ginseng have been developed. . In particular, black ginseng means ginseng that has changed to black color through several steaming and drying processes, and the ginseng saponin that is basically present during several growth and drying processes is not lost, and is present only in processed ginseng. Since the content of ginseng saponin is known to be enhanced, research on a method of more effectively producing such black ginseng has been actively conducted.
예를 들어, 한국특허등록 제 496418호에는 세척한 세미삼을 60 내지 70℃로 1.5 내지 2 시간 동안 1차 증숙한 후, 수분함량이 28%에 도달할 때까지 건조한 다음, 상기 공정을 다시 4회에 걸쳐 반복한 후, 고압증숙기에서 135℃의 온도로 약 2 내지 3 시간 동안 고압 증숙하고, 열풍회전건조기에서 60 내지 70℃에서 수분 25 % 까지 건조시킨 다음, 상기 공정을 다시 4회에 걸쳐 반복하고, 이를 벌크건조기에서 최종 수분함량 14%로 건조한 후, 이물질을 제거하는 공정을 포함하는 흑미삼의 제조방법이 개시되어 있고, 한국 특허공개 제 2003-0005089호에는 인삼을 세척한 후, 몸체와 미삼으로 분리하고, 인삼의 몸체와 미삼의 수분함량이 14%이하가 되도록 건조시킨 다음, 이 과정을 7 회 이상 반복하는 공정을 포함하는 흑삼 또는 흑미삼의 제조방법이 개시되어 있다.For example, in Korean Patent Registration No. 496418, the washed semi ginseng is first steamed at 60 to 70 ° C. for 1.5 to 2 hours, dried until the moisture content reaches 28%, and then the process is repeated again. After repeated several times, high-pressure steaming at a temperature of 135 ℃ in a high pressure steamer for about 2 to 3 hours, dried in a hot air rotary dryer to 60% moisture at 60 to 70 ℃, and then the process again After repeating, drying it to a final moisture content of 14% in a bulk dryer, there is disclosed a method for producing black rice, including the step of removing foreign matters, Korean Patent Publication No. 2003-0005089 after washing ginseng, A method for preparing black ginseng or black ginseng is disclosed that includes separating the body and the ginseng, drying the ginseng body and the ginseng to 14% or less, and then repeating the process seven or more times.
그러나, 이들 방법을 이용하여 제조된 흑삼은 대체로 인삼사포닌 성분을 높은 함량으로 포함하고 있으나, 보다 간단한 방법에 의하여 제조되는 홍삼과 비교할 때, 뚜렷한 장점이 없는 것으로 알려져 있다. 즉, 흑삼을 제조하기 위하여는 홍삼을 제조할 경우보다도 증숙 및 건조횟수가 증가하거나 또는 고압증숙기와 같은 추가적인 장비를 필요로 함에도 불구하고, 최종적으로 제조된 흑삼에 포함된 인삼사포닌 성분의 함량은 홍삼에 포함된 것에 비하여 그다지 큰 차이를 나타내지 않으므로, 혹삼이 홍삼에 비하여 뚜렷한 장점이 없고, 오히려 산업적인 관점에서 볼때는 흑삼은 홍삼보다도 경제성이 낮은 것으로 여겨지고 있다.However, although black ginseng prepared using these methods generally contains a high content of ginseng saponin components, it is known that there is no obvious advantage when compared to red ginseng prepared by a simpler method. That is, in order to manufacture black ginseng, although the number of steaming and drying is increased or additional equipment such as a high pressure steamer is required than the manufacture of red ginseng, the content of the ginseng saponin component included in the finally prepared black ginseng is red ginseng Since it does not show much difference compared to that contained in, ginseng has no distinct advantage over red ginseng, and from an industrial point of view, black ginseng is considered to be less economical than red ginseng.
이러한 흑삼의 문제점은 흑삼에 포함된 인삼사포닌 성분의 함량이 홍삼의 것과 현저한 차이를 나타내지 못한다는 것에 기인하므로, 흑삼에 포함된 인삼사포닌 성분의 함량, 특히 가공된 인삼에만 존재하는 인삼사포닌 성분의 함량을 홍삼의 것에 비하여 현저하게 증가시킬 수 있다면, 상술한 흑삼의 문제점을 해결할 수 있을 것으로 기대되고 있으나, 아직까지는 별다른 성과가 보고되지 않고 있는 실정이다.The problem of black ginseng is that the content of ginseng saponin contained in black ginseng does not show a significant difference from that of red ginseng, and therefore, the content of ginseng saponin contained in black ginseng, especially the content of ginseng saponin present in processed ginseng If it can be significantly increased compared to that of the red ginseng, it is expected that the above-mentioned problem of the black ginseng can be solved, but the situation has not been reported yet.
본 발명자들은 가공된 인삼에만 존재하는 인삼사포닌 성분의 함량이 증가된 흑삼을 제조하는 방법을 개발하고자 예의 연구노력한 결과, 상압에서 증숙하는 공정과 고압에서 증숙하는 공정을 교대로 반복하는 방법을 사용할 경우, 가공된 인삼 에만 존재하는 인삼사포닌 성분 중에서 항암효과를 나타내는 Rg3와 Rh2의 함량이 증가된 흑삼 및 흑삼 추출물을 제조할 수 있음을 확인하고, 본 발명을 완성하게 되었다.The present inventors have diligently researched to develop a method for producing black ginseng with increased content of ginseng saponin components present only in processed ginseng, and when using a method of alternately repeating the steaming process at atmospheric pressure and the steaming process at high pressure. In the ginseng saponin components present only in processed ginseng, it was confirmed that black ginseng and black ginseng extracts having an increased anti-cancer effect of Rg3 and Rh2 could be prepared, thereby completing the present invention.
결국, 본 발명의 첫 번째 목적은 항암효과를 나타내는 인삼사포닌 성분인 Rg3와 Rh2의 함량이 증가된 흑삼의 제조방법을 제공하는 것이다.After all, the first object of the present invention is to provide a method for producing black ginseng with increased content of Rg3 and Rh2, which is a ginseng saponin component exhibiting an anticancer effect.
본 발명의 두 번째 목적은 상기 방법으로 제조되어, 항암효과를 나타내는 인삼사포닌 성분인 Rg3와 Rh2의 함량이 증가된 흑삼을 제공하는 것이다.The second object of the present invention is to provide a black ginseng prepared by the above method, the content of Rg3 and Rh2, which is a ginseng saponin component having an anticancer effect, is increased.
본 발명의 세 번째 목적은 상기 흑삼으로부터 흑삼 추출물을 제조하는 방법을 제공하는 것이다.It is a third object of the present invention to provide a method for preparing black ginseng extract from the black ginseng.
본 발명의 네 번째 목적은 상기 방법으로 제조되어, 항암효과를 나타내는 인삼사포닌 성분인 Rg3와 Rh2의 함량이 증가된 흑삼 추출물을 제공하는 것이다.A fourth object of the present invention is to provide a black ginseng extract prepared by the above method, the content of Rg3 and Rh2, which is a ginseng saponin component exhibiting an anticancer effect.
본 발명의 다섯 번째 목적은 상기 흑삼 또는 흑삼 추출물을 유효성분으로 포함하는 암질환의 예방 및 치료용 약학 조성물을 제공하는 것이다.A fifth object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of cancer diseases comprising the black ginseng or black ginseng extract as an active ingredient.
본 발명의 여섯 번째 목적은 상기 흑삼 또는 흑삼 추출물을 포함하는 항암 건강기능식품을 제공하는 것이다.A sixth object of the present invention is to provide an anticancer health functional food comprising the black ginseng or black ginseng extract.
본 발명의 제조방법을 이용할 경우, 항암효과를 나타내는 인삼사포닌 성분인 Rg3와 Rh2의 함량이 증가된 흑삼 및 흑삼 추출물을 제조할 수 있으므로, 항암치료제, 항암예방제 및 항암 건강기능식품의 개발에 널리 활용될 수 있을 것이다.When using the production method of the present invention, black ginseng and black ginseng extracts with increased content of Rg3 and Rh2, which are anti-cancer ginseng saponin components, can be prepared, and thus widely used in the development of anticancer drugs, anticancer agents, and anti-cancer health foods. Could be.
본 발명자들은 가공된 인삼에만 존재하는 인삼사포닌 성분의 함량이 증진된 흑삼을 제조하는 방법을 모색하고자, 먼저 증숙하는 공정의 횟수에 따라, 흑삼에 포함된 가공된 인삼에만 존재하는 인삼사포닌 성분인 Rg2, Rg3, Rh1 또는 Rh2의 함량이 변화되는지를 확인하였다. 그 결과, 증숙공정의 횟수가 증가할 경우, 흑삼에 포함된 Rg2 및 Rh1의 함량은 별다른 변화를 나타내지 않았으나, Rg3 및 Rh2의 함량은 증가하는 양상을 나타내었다. 그러나, 10회 이상 증숙할 경우에는 Rg3와 Rh2의 함량이 오히려 감소하는 경향을 나타냄을 알 수 있었는 바, 9번 증숙하고 9번 건조시키는 이른바 "구증구포(九蒸九曝)" 방식이 가장 바람직함을 알 수 있었다.The inventors of the present invention, in order to find a method for producing black ginseng with enhanced content of ginseng saponin components present only in processed ginseng, according to the number of steaming processes, Rg2 which is a ginseng saponin component present only in processed ginseng included in black ginseng It was confirmed whether the content of Rg3, Rh1 or Rh2 is changed. As a result, when the number of steaming process increases, the contents of Rg2 and Rh1 contained in black ginseng did not change much, but the contents of Rg3 and Rh2 increased. However, when steaming more than 10 times, it was found that the contents of Rg3 and Rh2 tended to decrease, so the so-called "gujeungpo" method of steaming 9 times and drying 9 times was most preferable. I could see.
한편, 이처럼 9회 증숙하는 공정을 사용하여도 흑삼에 포함된 Rg3와 Rh2의 함량증가 정도는 현저하지 않았으므로, 흑삼에 포함된 Rg3와 Rh2의 함량을 현저하게 증가시킬 수 있는 방법을 개발하고자 하였는 바, 고압에서 증숙하는 공정을 수행할 경우, 상압에서 증숙할 때 보다도 흑삼에 포함된 Rg3와 Rh2의 함량을 현저하게 증가됨을 확인할 수 있었으나, 고압에서 증숙할 경우에는 발암물질로 알려진 벤조피렌(benzopyrene)의 함량이 급격하게 증가함을 알 수 있었다.On the other hand, even using this 9-steaming process, the increase in the content of Rg3 and Rh2 contained in black ginseng was not remarkable, and therefore, it was intended to develop a method to significantly increase the content of Rg3 and Rh2 contained in black ginseng. Bar, when steaming at high pressure, the content of Rg3 and Rh2 contained in black ginseng was significantly increased than steaming at normal pressure, but when steaming at high pressure, benzopyrene, known as a carcinogen, was observed. It can be seen that the content of is increased rapidly.
상기 벤조피렌은 고압에서 증숙하는 공정을 2회 반복할 때 까지는 크게 증가하지 않았으므로, 고압에서 증숙하는 공정을 2회 수행하고, 상압에서 증숙하는 공 정을 7회 수행하여 흑삼을 제조한 결과, 상압에서 증숙하는 공정을 9회 수행할 경우보다는 Rg3와 Rh2의 함량이 현저하게 증가되고, 벤조피렌의 함량은 거의 증가되지 않음을 확인하였다. 이에, 고압에서 증숙하는 공정과 상압에서 증숙하는 공정을 순서적으로 적절하게 설정하여, 가장 효과적으로 Rg3와 Rh2의 함량을 증가시킬 수 있는 방법을 검토한 결과, 제 1회 및 제 6회에 고압으로 증숙하는 공정을 수행할 경우, Rg3와 Rh2의 함량이 가장 높은 흑삼을 제조할 수 있음을 알 수 있었다.The benzopyrene did not increase greatly until the process of steaming at high pressure was repeated twice, and thus, black ginseng was prepared by performing the process of steaming at high pressure twice and performing the process of steaming at atmospheric pressure seven times, and at atmospheric pressure. Rg3 and Rh2 content was significantly increased, and the content of benzopyrene was hardly increased, rather than performing nine times the steaming process. Therefore, the method of increasing the content of Rg3 and Rh2 in the most effective manner by setting appropriately the process of steaming at high pressure and the process of steaming at atmospheric pressure in order is considered as the first and sixth time. When the steaming process is performed, it can be seen that black ginseng having the highest content of Rg3 and Rh2 can be prepared.
한편, 상기 방법으로 제조된 흑삼의 항암활성을 조사하기 위하여, 본 발명의 방법으로 제조한 흑삼과 종래의 방법으로 제조한 흑삼으로부터 각각 흑삼 추출물을 수득하고, 이를 실험실 조건에서 배양된 폐암세포주에 처리하고 배양하였다. 그 결과, 본 발명의 방법으로 제조한 흑삼이 종래의 방법으로 제조한 흑삼보다도 폐암세포주의 생존율을 더욱 저하시켰으므로, 본 발명의 방법으로 제조한 흑삼이 종래의 방법으로 제조한 흑삼보다도 우수한 암 치료효과를 나타냄을 알 수 있었다.On the other hand, in order to investigate the anticancer activity of the black ginseng prepared by the above method, the black ginseng extract obtained from the black ginseng prepared by the method of the present invention and the black ginseng prepared by the conventional method, respectively, and treated to the lung cancer cell line cultured under laboratory conditions And incubated. As a result, the black ginseng prepared by the method of the present invention lowered the survival rate of lung cancer cell lines more than the black ginseng prepared by the conventional method. Therefore, the black ginseng prepared by the method of the present invention is superior to the black ginseng prepared by the conventional method. It can be seen that the effect.
아울러, 상기 본 발명의 방법으로 제조한 흑삼의 항암활성이 생체조건에서도 나타나는지를 확인하기 위하여, 상기 제조한 각각의 흑삼 추출물을 전이성 암세포의 일종인 B6 멜라노마(melanoma) 세포주와 함께 마우스에 주사하고 사육한 다음, 폐를 적출하여 폐의 표면에 나타나는 멜라노마 콜로니의 수를 계수하였다. 그 결과, 본 발명의 방법으로 제조한 흑삼이 종래의 방법으로 제조한 흑삼보다도 효과적으로 외부에서 주사된 B16 멜라노마 세포의 전이활성을 억제하여, 폐의 표면에 나타나는 멜라노마 콜로니의 수를 더욱 감소시켰는 바, 본 발명의 방법으로 제조한 흑삼이 종래의 방법으로 제조한 흑삼보다도 우수한 암 예방효과를 나타냄을 알 수 있었다.In addition, in order to confirm whether the anticancer activity of the black ginseng prepared by the method of the present invention is shown in vivo, each of the prepared black ginseng extracts is injected into the mouse together with the B6 melanoma cell line, which is a kind of metastatic cancer cells. After breeding, the lungs were removed and the number of melanoma colonies appearing on the surface of the lungs was counted. As a result, black ginseng prepared by the method of the present invention inhibited the metastatic activity of B16 melanoma cells injected externally more effectively than black ginseng prepared by the conventional method, further reducing the number of melanoma colonies appearing on the surface of the lung. It was found that the black ginseng prepared by the method of the present invention exhibited superior cancer prevention effects than the black ginseng prepared by the conventional method.
결국, 본 발명의 Rg3 및 Rh2의 함량이 증가된 흑삼의 제조방법은 건조된 인삼을 90 내지 110℃에서 1 내지 3시간동안 증숙한 다음, 50 내지 70℃에서 1 내지 3시간 동안 건조시키는 공정을 9회 반복수행하여 흑삼을 제조하는 방법에 있어서, 제 1회 및 제 6회차 증숙공정을 5 내지 15기압의 압력하에서 수행하는 것을 특징으로 한다. 이때, 인삼을 증숙하는 온도 및 시간조건은 통상의 인삼증숙시 사용되는 온도 및 시간조건과 대체로 동일하고, 증숙된 인삼을 건조하는 온도 및 시간조건 역시 통상의 인삼건조시 사용되는 온도 및 시간조건과 대체로 동일하다. 또한, 5 내지 15기압의 압력하에서 2회 증숙할 경우에는, Rg3 및 Rh2의 함량이 현저히 증가하면서도 발암물질로 알려진 벤조피렌의 함량은 증가하지 않았으나, 15기압 보다 높은 기압조건하에 증숙하거나 3회 이상 증숙할 경우에는, 벤조피렌의 함량이 과도하게 증가하고, 5기압 보다 낮은 기압조건하에 증숙하거나 고압조건에서 1회만 증숙할 경우에는 Rg3 및 Rh2의 함량이 증가하지 않았다.As a result, the manufacturing method of the black ginseng with the increased content of Rg3 and Rh2 of the present invention is to steam the dried ginseng for 1 to 3 hours at 90 to 110 ℃, and then to dry for 1 to 3 hours at 50 to 70 ℃ In the method for producing black ginseng by performing nine times, the first and sixth steaming step is performed under a pressure of 5 to 15 atm. In this case, the temperature and time conditions for steaming ginseng are generally the same as the temperature and time conditions used for steaming conventional ginseng, and the temperature and time conditions for drying steamed ginseng are also different from those used for normal ginseng drying. Mostly the same. In addition, when steaming twice under a pressure of 5 to 15 atm, the content of Rg3 and Rh2 was significantly increased, but the content of benzopyrene, which is known to be a carcinogen, did not increase. In this case, the content of benzopyrene was excessively increased, and the content of Rg3 and Rh2 did not increase when steaming under atmospheric pressure lower than 5 atm or steaming only once under high pressure.
본 발명의 다른 실시태양에 의하면, 상기 방법으로 제조되어 Rg3 및 Rh2의 함량이 증가된 흑삼을 분쇄하고, 흑삼에 대하여 3 내지 7배(중량비)의 물을 가하여 3 내지 7시간 동안 방치한 다음, 탄소수 1 내지 4의 저급알코올을 추출용매로 사용하여 추출함으로써, Rg3 및 Rh2의 함량이 증가된 흑삼 추출물을 제조할 수 있다. 이때, 추출은 특별히 이에 제한되지 않으나, 상기 물에 대하여 5 내지 15배(부피비)의 에탄올을 가하여, 30 내지 70℃에서 1 내지 5시간 동안 추출한 다음, 여과하고, 용매를 제거하여 수행함이 바람직하다.According to another embodiment of the present invention, black ginseng prepared by the above method to increase the content of Rg3 and Rh2 is pulverized, and left to stand for 3 to 7 hours by adding 3 to 7 times (weight ratio) of water to the black ginseng, By extracting the lower alcohol having 1 to 4 carbon atoms as the extraction solvent, black ginseng extract with increased content of Rg3 and Rh2 can be prepared. At this time, the extraction is not particularly limited, but 5 to 15 times (volume ratio) of ethanol is added to the water, it is preferably extracted for 1 to 5 hours at 30 to 70 ℃, then filtered and the solvent is preferably carried out. .
본 발명의 다른 실시태양에 의하면, 상기 제조된 흑삼 또는 흑삼 추출물에 고함량으로 포함된 Rg3 및 Rh2는 그의 안전성과 우수한 항암활성이 이미 공지되었으므로(참조: Hideyuki Nakata, et al., Cancer Science, 89(7): 733-740, 2005; Y.K. Yue, et al., Biochemical Pharmacology, 72(4): 437-445, 2006), 종래의 홍삼보다도 Rg3 및 Rh2의 함량이 높은 본 발명의 흑삼 또는 흑삼 추출물이 안전하면서도 보다 우수한 항암활성을 나타냄을 자명하다 하겠는 바, 본 발명의 흑삼 또는 흑삼 추출물을 암질환의 예방 및 치료용 약학조성물의 유효성분으로 사용할 수 있다. 이때, 상기 암질환은 일반적인 암 질환을 포함하며, 바람직하게는 위암, 결장암, 유방암, 폐암, 비소세포성폐암(non-small cell lung cancer), 골암(bone tumor), 췌장암, 간암, 피부암, 두부 또는 경부암, 피부 또는 안구 내 흑색종, 자궁암, 난소암, 대장암, 소장암, 직장암, 항문부근암, 나팔관암종, 자궁내막암종, 질암종, 음문암종, 호킨병(Hodgkin's disease), 식도암, 소장암, 임파선암, 방광암, 담낭암, 내분비선암, 갑상선암, 부갑상선암, 부신암, 연조직 육종, 요도암, 음경암, 전립선암, 만성 또는 급성 백혈병, 림프구 림프종, 방광암, 신장 또는 수뇨관 암, 신장세포 암종, 신장골반 암종, 중추신경계(CNS: central nervous system) 종양, 1차 CNS 림프종, 척수 종양, 뇌간 신경교종 또는 뇌하수체 선종이다.According to another embodiment of the present invention, Rg3 and Rh2, which are contained in the black ginseng or black ginseng extract prepared in high amounts, have already been known for their safety and excellent anticancer activity (see Hideyuki Nakata, et al., Cancer Science, 89). (7): 733-740, 2005; YK Yue, et al., Biochemical Pharmacology, 72 (4): 437-445, 2006), black ginseng or black ginseng extract of the present invention having a higher content of Rg3 and Rh2 than conventional red ginseng It will be apparent that this safe and excellent anti-cancer activity, black ginseng or black ginseng extract of the present invention can be used as an active ingredient of the pharmaceutical composition for the prevention and treatment of cancer diseases. In this case, the cancer disease includes a general cancer disease, preferably gastric cancer, colon cancer, breast cancer, lung cancer, non-small cell lung cancer (non-small cell lung cancer), bone cancer (bone tumor), pancreatic cancer, liver cancer, skin cancer, head Or cervical cancer, skin or ocular melanoma, uterine cancer, ovarian cancer, colorectal cancer, small intestine cancer, rectal cancer, anal muscle cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal carcinoma, vulvar carcinoma, Hogkin's disease, esophageal cancer, small intestine Cancer, lymph gland cancer, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocyte lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma , Renal pelvic carcinoma, central nervous system (CNS) tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma or pituitary adenoma.
한편, 본 발명의 약학조성물의 유효성분으로 함유되는 흑삼 또는 흑삼 추출물은 약학적으로 허용가능한 결합제(예, 폴리비닐피롤리돈, 하이드록시프로필셀룰로오스), 붕해제(예, 카복시메틸셀룰로오스칼슘, 전분글리콜산나트륨), 희석제(예, 옥수수전분, 유당, 콩기름, 결정셀룰로오스, 만니톨), 활택제(예, 스테아린산 마그네슘, 탈크), 미제(예, 백당, 과당, 솔비톨, 아스파탐), 안정제(카복시메틸셀룰로오스나트륨, 알파 또는 베타 싸이클로덱스트린, 구연산, 백납), 보존료(예, 파라옥시안식향산메틸, 파라옥시안식향산프로필, 안식향산나트륨) 및 향료(예, 에틸바닐린, 마스킹후레바, 멘톨후라보노, 허브향)와 혼합하여, 정제, 캅셀제, 연질캅셀제, 액제, 연고제, 주사제 등의 약학적 제제로 제조될 수 있다. On the other hand, black ginseng or black ginseng extract contained as an active ingredient of the pharmaceutical composition of the present invention is a pharmaceutically acceptable binder (eg polyvinylpyrrolidone, hydroxypropyl cellulose), disintegrant (eg carboxymethyl cellulose calcium, starch) Sodium glycolate), diluents (e.g. corn starch, lactose, soybean oil, crystalline cellulose, mannitol), lubricants (e.g. magnesium stearate, talc), crudes (e.g. white sugar, fructose, sorbitol, aspartame), stabilizers (carboxymethyl Sodium cellulose, alpha or beta cyclodextrin, citric acid, white lead), preservatives (e.g. methyl paraoxybenzoate, propyl paraoxybenzoate, sodium benzoate) and flavorings (e.g. ethyl vanillin, masking flavor, menthol flavono, herbal flavor) It can be mixed with and prepared into pharmaceutical preparations such as tablets, capsules, soft capsules, solutions, ointments, injections and the like.
급성독성실험Acute Toxicity Test
본 발명의 약학조성물의 유효성분인 흑삼 또는 흑삼 추출물에 포함된 Rg3 및 Rh2는 종래로부터 항암활성 및 안전성이 입증된 것이고, 흑삼의 원료인 인삼 및 흑삼과 유사한 방법으로 제조된 홍삼 역시 종래로부터 안정성이 이미 입증된 것이므로, 흑삼에 대한 별도의 급성독성실험은 수행하지 않았다.Rg3 and Rh2 contained in black ginseng or black ginseng extract of the active ingredient of the pharmaceutical composition of the present invention has been proven anti-cancer activity and safety from the past, and red ginseng prepared by methods similar to ginseng and black ginseng, which are raw materials of black ginseng, has also been conventionally stable. As already proven, no separate acute toxicity studies were conducted for black ginseng.
유효량Effective amount
본 발명의 약학조성물의 유효성분으로 함유되는 흑삼 또는 흑삼 추출물의 투여량은 환자의 연령, 성별, 증상, 투여방법 또는 예방목적에 따라, 흑삼의 경우 체중 kg 당 각각 1일 20 내지 200mg, 흑삼 추출물의 경우 체중 kg 당 각각 1일 0.2 내지 2mg을 투여함이 바람직하고, 특이 증상을 나타내는 환자에 대한 투여용량 수준은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율, 질환의 중증도 등에 따라 당업자가 투여량을 변화시킬 수도 있다. Dosage of black ginseng or black ginseng extract contained as an active ingredient of the pharmaceutical composition of the present invention, depending on the age, sex, symptoms, administration method or purpose of the patient, in the case of black ginseng 20 to 200mg per kg body weight each day, black ginseng extract In the case of the body weight is preferably administered 0.2 to 2mg per kg each day, the dosage level for patients with specific symptoms is the weight, age, sex, health status, diet, time of administration, method of administration, excretion rate of the patient The dosage may be changed by those skilled in the art according to the severity of the disease.
본 발명의 또 다른 실시태양에 의하면, 상기 항암효과를 나타내는 성분인 Rg3 및 Rh2의 함량이 증가된 흑삼 또는 흑삼 추출물은 독성 및 부작용이 거의 없어, 장시간 상식하여도 안심하고 사용할 수 있으므로, 항암 건강기능식품의 유효성분으로 사용할 수 있다. 이때, 식품의 형태는 이에 특별히 제한되지 않으나, 선식, 면류, 과자류, 음료류, 육류, 생선류, 나물류, 찌게류 또는 밥류 등을 포함하는 다양한 식품의 제조시 첨가하여 제조될 수도 있고, 식품에 포함되는 전기 조성물의 함량은 이에 특별히 제한되지는 않으나, 흑삼 또는 흑삼 추출물을 분말화하여 선식의 형태로 섭취하는 경우에는 흑삼은 식품의 최종중량에 대하여 1 내지 50중량%로 포함함이 바람직하고, 흑삼 추출물을 식품의 최종중량에 대하여 0.5 내지 5중량%로 포함함이 바람직하며, 상기 흑삼 또는 흑삼 추출물을 면류, 과자류, 음료류, 육류, 생선류, 나물류, 찌게류 또는 밥류 등의 식품에 첨가하여 섭취하는 경우에는, 흑삼은 식품의 최종중량에 대하여 1 내지 10중량%로 포함함이 바람직하고, 흑삼 추출물은 식품의 최종중량에 대하여 0.1 내지 1중량%로 포함함이 바람직하다.According to another embodiment of the present invention, black ginseng or black ginseng extract with increased contents of Rg3 and Rh2, which have the anti-cancer effect, has little toxicity and side effects, and thus can be used safely for a long time. It can be used as an active ingredient in food. At this time, the form of the food is not particularly limited, but may be prepared by adding in the manufacture of a variety of foods, including wire, noodles, confectionery, beverages, meat, fish, herbs, steamed rice or rice, etc. The content of the electrical composition is not particularly limited thereto, but when the black ginseng or black ginseng extract is ingested in the form of powder, the black ginseng is preferably contained in an amount of 1 to 50% by weight based on the final weight of the food, and the black ginseng extract It is preferable to include 0.5 to 5% by weight relative to the final weight of the food, when the black ginseng or black ginseng extract is added to foods such as noodles, confectionery, beverages, meat, fish, herbs, steamed rice or rice In the black ginseng is preferably contained 1 to 10% by weight based on the final weight of the food, the black ginseng extract is 0.1 to 1 of the final weight of the food It is preferable to include in amount%.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예 1: 흑삼의 제조 및 성분 분석 Example 1 Preparation of Black Ginseng and Component Analysis
실시예 1-1: 증숙 및 건조에 의한 흑삼의 제조 Example 1-1 Preparation of Black Ginseng by Steaming and Drying
금산에서 생산되어 유통되는 5년근 수삼을 구입한 후, 스크류 세척기에 넣고 10분간 총 3회 반복해서 세척하고, 증숙시에 수삼이 손상되는 것을 방지하기 위하여, 40℃에서 24시간동안 방치하여 건조시켰다. 이어, 증숙기에 넣고 100℃에서 2시간동안 증숙시키고, 60℃에서 2시간 동안 건조시키는 공정을 12회 반복하여 흑삼을 제조하고, 매회 공정이 완료된 시점에서 시료를 채취하여, 총 12개의 흑삼시료를 채취하였다.After purchasing 5-year-old ginseng produced and distributed in Geumsan, it was put in a screw washer and washed three times for a total of 10 minutes. In order to prevent the fresh ginseng from being damaged during steaming, it was left to dry at 40 ° C. for 24 hours. . Subsequently, the black ginseng was prepared by repeating the process of steaming at 100 ° C. for 2 hours and drying at 60 ° C. for 2 hours. The sample was taken every time the process was completed, and a total of 12 black ginseng samples were collected. Was collected.
실시예 1-2: 흑삼 추출물의 제조 및 성분분석 Example 1-2 : Preparation and Analysis of Black Ginseng Extract
상기 채취한 각 흑삼시료로부터 흑삼추출물을 수득하고, 상기 흑삼추출물에 포함된 인삼사포닌 성분 중에서 가공된 인삼에만 존재하는 Rg2, Rg3, Rh1 및 Rh2의 함량을 측정하였다.Black ginseng extract was obtained from each of the collected black ginseng samples, and the contents of Rg2, Rg3, Rh1 and Rh2 present only in processed ginseng among the ginseng saponin components included in the black ginseng extract were measured.
구체적으로, 상기 채취한 각 시료 20g을 마쇄하고, 이에 100㎖의 물을 가하여 실온에서 5시간동안 방치하였다. 이어, 에탄올 1L를 가하여 50℃에서 3시간 동안 추출하고, 이를 여과한 다음, 감압농축기에 적용하여 농축하고, 동결건조하여 고체상의 흑삼 추출물을 각각 수득하였다. Specifically, 20 g of each sample collected was crushed, and 100 ml of water was added thereto, and left for 5 hours at room temperature. Then, 1 L of ethanol was added and extracted at 50 ° C. for 3 hours, filtered, and then concentrated by applying to a vacuum concentrator, and lyophilized to obtain a solid black ginseng extract.
그런 다음, 상기 각각의 고체상의 흑삼 추출물 3.2g에 물 200㎖를 가하여 현탁시키고, 이에 에테르 200㎖를 가하고, 격렬히 혼합한 다음, 이를 분별깔대기에 가하고 실온에서 1시간 동안 방치한 다음, 수층을 수득하였다. 상기 수층에 수포화 부탄올 200㎖를 가하여 부탄올 추출분획을 수득하고, 이로부터 부탄올을 제거하여, 고체상의 분석시료를 각각 수득하였다.Then, 200 g of water was added to 3.2 g of each solid black ginseng extract, suspended, 200 mL of ether was added thereto, mixed vigorously, added to a separatory funnel, and allowed to stand at room temperature for 1 hour, after which a water layer was obtained. It was. 200 mL of saturated butanol was added to the aqueous layer to obtain a butanol extract fraction, and butanol was removed therefrom to obtain a solid sample.
상기 수득한 각 분석시료 20㎎에 메탄올 1㎖을 가하여 용해시키고, 0.45㎛ 필터로 여과한 다음, 하기 조건으로 HPLC에 적용하여 Rg2, Rg3, Rh1, Rh2 및 벤조피렌(benzopyrene)의 함량을 측정하였다(참조: 표 1 및 표 2). 벤조피렌은 증숙시에 탄화된 흑삼으로부터 검출되는 성분으로서, 암 유발물질 중의 하나로 알려져 있는 바, 벤조피렌의 함량은 증숙공정에 의한 부작용의 발생여부를 확인하기 위한 지표로 사용하였다.1 mL of methanol was added to 20 mg of the analytical sample thus obtained, dissolved, filtered through a 0.45 μm filter, and then subjected to HPLC under the following conditions to determine the contents of Rg2, Rg3, Rh1, Rh2 and benzopyrene. See Table 1 and Table 2). Benzopyrene is a component that is detected from carbonized black ginseng during steaming, and is known as one of cancer causing substances. The content of benzopyrene was used as an indicator for confirming the occurrence of side effects caused by the steaming process.
상기 표 2에서 보듯이, 증숙공정의 횟수가 증가할 경우, 흑삼에 포함된 Rg2 및 Rh1의 함량은 별다른 변화를 나타내지 않았으나, Rg3 및 Rh2의 함량은 증가하는 양상을 나타내었다. 그러나, 10회 이상 증숙할 경우에는 Rg3와 Rh2의 함량이 오히려 감소하는 경향을 나타냄을 알 수 있었는 바, 9번 증숙하고 9번 건조시키는 이른바 "구증구포(九蒸九曝)" 방식이 가장 바람직함을 알 수 있었다.As shown in Table 2, when the number of steaming process increases, the content of Rg2 and Rh1 contained in the black ginseng did not change much, but the content of Rg3 and Rh2 increased. However, when steaming more than 10 times, it was found that the contents of Rg3 and Rh2 tended to decrease, so the so-called "gujeungpo" method of steaming 9 times and drying 9 times was most preferable. I could see.
실시예 2: 고압조건하에서 흑삼의 제조 Example 2 Preparation of Black Ginseng Under High Pressure Conditions
상기 실시예 1의 결과에서 보듯이, 9회 증숙하여도 흑삼에 포함된 Rg3와 Rh2의 함량증가 정도는 현저하지 않았음을 알 수 있었다. 이에, 흑삼에 포함된 Rg3와 Rh2의 함량을 증가시키고자, 10기압의 조건에서 증숙공정을 수행하는 것을 제외하고는, 상기 실시예 1과 동일한 방법으로 흑삼을 제조하고, 이로부터 흑삼추출물을 수득한 다음, 흑삼추출물에 포함된 Rg3, Rh2 및 벤조피렌의 함량을 측정하였다(참조: 표 3).As shown in the result of Example 1, it was found that even after 9 steaming, the increase in the content of Rg3 and Rh2 contained in the black ginseng was not significant. Thus, to increase the contents of Rg3 and Rh2 contained in the black ginseng, except that the steaming process is carried out under the condition of 10 atm, black ginseng is prepared in the same manner as in Example 1, and black ginseng extract is obtained therefrom. Next, the contents of Rg3, Rh2 and benzopyrene contained in the black ginseng extract were measured (see Table 3).
상기 표 3에서 보듯이, 고압조건하에서 증숙할 경우에는 상압에서 증숙할 경우보다도 Rg3 및 Rh2의 함량이 현저하게 증가되었으나, 벤조피렌의 함량역시 급격히 증가됨을 알 수 있었다. 그러나, 암 유발물질로 알려진 벤조피렌의 함량이 증가될 경우에는 의약의 유효성분으로 사용될 수 없는 바, 이러한 문제점을 해결하여야만 하였다.As shown in Table 3, when steaming under high pressure conditions, the contents of Rg3 and Rh2 were significantly increased than steaming at normal pressure, but it was also found that the content of benzopyrene also increased rapidly. However, when the content of benzopyrene, which is known as a cancer causing substance, is increased, it cannot be used as an active ingredient of medicine, and this problem has to be solved.
아울러, 압력조건을 변화시키면서, 각각의 흑삼을 제조하고, 이로부터 각 흑삼 추출물을 수득한 다음, 이들에 포함된 Rg3, Rh2 및 벤조피렌의 함량을 측정하였다.In addition, while changing the pressure conditions, each black ginseng was prepared, and each black ginseng extract was obtained therefrom, and then the contents of Rg3, Rh2 and benzopyrene were measured.
구체적으로, 1기압, 5기압, 10기압, 15기압 또는 20기압의 조건에서 증숙공정을 수행하는 것을 제외하고는, 상기 실시예 1과 동일한 방법으로 흑삼을 제조하고, 이로부터 흑삼추출물을 수득한 다음, 상기 흑삼추출물에 포함된 Rg3, Rh2 및 벤조피렌의 함량을 측정하였다(참조: 표 4a 내지 4c).Specifically, except that the steaming process is carried out under the conditions of 1 atm, 5 atm, 10 atm, 15 atm or 20 atm, black ginseng was prepared in the same manner as in Example 1, and black ginseng extract was obtained therefrom. Next, the contents of Rg3, Rh2 and benzopyrene contained in the black ginseng extract were measured (see Tables 4a to 4c).
상기 표 4a에서 보듯이, 압력 및 증숙횟수가 증가할수록 Rg3의 함량이 증가되는 양상을 나타내었으나, 20기압의 압력에서는 Rg3의 함량의 증가율이 현저하게 감소됨을 알 수 있었다.As shown in Table 4a, the content of Rg3 increased as the pressure and the number of steaming increased, but it was found that the rate of increase of the content of Rg3 was significantly reduced at a pressure of 20 atm.
상기 표 4b에서 보듯이, 압력 및 증숙횟수가 증가할수록 Rh2의 함량이 증가되는 양상을 나타내었으나, 20기압의 압력에서는 Rh2의 함량의 증가율이 현저하게 감소됨을 알 수 있었다.As shown in Table 4b, the Rh2 content was increased as the pressure and the number of steaming increases, but it was found that the increase rate of the Rh2 content was significantly reduced at a pressure of 20 atm.
상기 표 4c에서 보듯이, 압력 및 증숙횟수가 증가할수록 벤조피렌의 함량이 급격히 증가되는 양상을 나타내었고, Rg3 및 Rh2의 경우와는 달리 20기압의 압력에서도 벤조피렌 함량의 증가율이 감소되지 않고 오히려 증가하는 양상을 나타내었으며, 단 1회 증숙한 경우에도 식품에서 허용되는 기준값인 1ppb를 초과하는 값을 나타내었으므로, 20기압의 조건으로 증숙하는 것은 바람직하지 못함을 알 수 있었다. 아울러, 1기압에서 증숙할 경우에는 Rg3 및 Rh2의 함량이 낮은 수준을 나타내었다.As shown in Table 4c, the content of benzopyrene increased rapidly as the pressure and the number of steaming increases, and unlike the case of Rg3 and Rh2, the increase rate of benzopyrene content does not decrease even at a pressure of 20 atm. In the case of steaming only once, the value exceeded the standard value of 1ppb, which is acceptable in food, and it was found that steaming under the condition of 20 atm is not preferable. In addition, when steamed at 1 atm, the contents of Rg3 and Rh2 were low.
이상의 결과로부터, 고압조건에서 인삼을 증숙할 경우, 압력조건은 5 내지 15기압이 바람직함을 알 수 있었다.From the above results, it was found that when the ginseng is steamed under high pressure, the pressure is preferably 5 to 15 atm.
한편, 상기 표 3 및 표 4a 내지 표 4c에서 보듯이, 5 내지 15기압의 압력조건에서 2회 증숙할 경우에는 벤조피렌의 함량이 크게 증가되지 않았으므로, 고압에서 2회 및 상압에서 7회 증숙하여 제조된 흑삼에서 Rg3, Rh2 및 벤조피렌의 함량이 어떻게 변화되는지 확인하였다. 구체적으로, 실시예 1의 방법으로 건조시킨 인삼을 증숙기에 넣고, 10기압의 압력하에서 100℃에서 2시간동안 증숙한 다음, 60℃에서 2시간 동안 건조시키는 공정을 2회 수행하고, 상압조건에서 100℃에서 2시간동안 증숙한 다음, 60℃에서 2시간 동안 건조시키는 공정을 7회 수행하여 흑삼을 제조하고, 매회 공정이 완료된 시점에서 시료를 채취하여, 총 9개의 흑삼시료를 채취하였다.On the other hand, as shown in Table 3 and Tables 4a to 4c, when steaming twice in a pressure condition of 5 to 15 atm did not significantly increase the content of benzopyrene, steamed twice at high pressure and 7 times at normal pressure It was confirmed how the content of Rg3, Rh2 and benzopyrene in the prepared black ginseng is changed. Specifically, the ginseng dried by the method of Example 1 was put into a steamer, steamed at 100 ° C. for 2 hours at a pressure of 10 atm, and then dried twice at 60 ° C. for 2 hours, under normal pressure. After steaming at 100 ° C. for 2 hours, drying was performed 7 times at 60 ° C. for 2 hours, black ginseng was prepared, and samples were taken at the completion of each process, and a total of 9 black ginseng samples were collected.
그런 다음, 실시예 1의 방법으로, 상기 채취된 각 시료로부터 흑삼추출물을 수득하고, 상기 흑삼추출물에 포함된 Rg3, Rh2 및 벤조피렌의 함량을 측정하였다(참조: 표 5).Then, by the method of Example 1, black ginseng extract was obtained from each sample collected, and the contents of Rg3, Rh2 and benzopyrene included in the black ginseng extract were measured (see Table 5).
상기 표 5에서 보듯이, 고압증숙을 2회 수행할 경우 Rg3, Rh2 및 벤조피렌의 함량이 증가하였으나, 상압증숙시에는 Rg3 및 Rh2의 함량만이 증가함을 알 수 있었다. As shown in Table 5, the contents of Rg3, Rh2 and benzopyrene increased when the high-pressure steaming was performed twice, but only the contents of Rg3 and Rh2 increased during atmospheric pressure steaming.
한편, 상기 표 5의 결과를 상기 표 2의 결과와 비교하면, 증숙이 수행될 때마다 Rg3 및 Rh2의 함량이 증가한다는 점에서는 서로 유사한 양상을 나타내었으나, 표 5에 개시된 Rg3 및 Rh2의 함량의 증가수준은 표 2의 것보다 우수함을 알 수 있었다. 아울러, 표 5에 개시된 Rg3 및 Rh2의 함량의 증가수준은 고압증숙시 뿐만 아니라 상압증숙시에도 표 2의 것보다 우수함을 확인할 수 있는 바, 고압증숙 단계와 상압증숙 단계를 혼합할 경우, Rg3 및 Rh2의 함량을 현저하게 증대시킬 수 있음을 알 수 있었다.On the other hand, when comparing the results of Table 5 with the results of Table 2, the content of Rg3 and Rh2 increases each time steaming is performed, but showed a similar aspect to each other, but the content of the contents of Rg3 and Rh2 disclosed in Table 5 The increase level was superior to that of Table 2. In addition, the increased levels of the contents of Rg3 and Rh2 disclosed in Table 5 can be confirmed that the superiority of those of Table 2 not only during high pressure steaming but also during normal pressure steaming, when mixing the high pressure steaming step and the normal pressure steaming step, Rg3 and It can be seen that the content of Rh2 can be significantly increased.
실시예 3: 고압증숙 및 상압증숙 단계의 최적화 Example 3 Optimization of High Pressure Steam and Normal Pressure Steam Stages
상기 실시예 2의 결과로부터, 고압증숙 단계와 상압증숙 단계를 혼합할 경우, Rg3 및 Rh2의 함량을 현저하게 증대시킬 수 있음을 알 수 있었는 바, Rg3 및 Rh2의 함량을 극대화할 수 있는 최적의 증숙조건을 확립하고자 하였다.From the results of Example 2, it can be seen that when mixing the high pressure steaming step and the normal pressure steaming step, the contents of Rg3 and Rh2 can be significantly increased, so that the optimum contents of Rg3 and Rh2 can be maximized. We tried to establish steam conditions.
먼저, 실시예 2의 결과로부터 고압증숙은 2회까지 가능함을 확인하였는 바, 하기의 표 6과 같이, 9회의 증숙공정 중에서, 2회의 고압증숙 공정을 할당하는 순서에 따라 각각의 실험군을 설정하였다. 이때, 고압증숙은 10기압 및 100℃에서 2시간동안 증숙시켜 수행하였다.First, it was confirmed that the high-pressure steaming can be performed up to two times from the results of Example 2. As shown in Table 6 below, each of the experimental groups was set in the order of allocating two high-pressure steaming processes among the nine steaming processes. . At this time, the high-pressure steaming was performed by steaming for 2 hours at 10 atm and 100 ℃.
13
14
15
16
17
18
19
23
24
25
2612
13
14
15
16
17
18
19
23
24
25
26
1회 및 3회
1회 및 4회
1회 및 5회
1회 및 6회
1회 및 7회
1회 및 8회
1회 및 9회
2회 및 3회
2회 및 4회
2회 및 5회
2회 및 6회Once and twice
1 and 3 times
1 and 4 times
1 and 5 times
1 and 6 times
1 and 7 times
1 and 8 times
1 and 9 times
2 times and 3 times
2 and 4 times
2 and 5 times
2 and 6 times
28
29
34
35
36
37
38
39
45
46
4727
28
29
34
35
36
37
38
39
45
46
47
2회 및 8회
2회 및 9회
3회 및 4회
3회 및 5회
3회 및 6회
3회 및 7회
3회 및 8회
3회 및 9회
4회 및 8회
4회 및 6회
4회 및 7회2 and 7 times
2 and 8 times
2 times and 9 times
3 times and 4 times
3 and 5 times
3 times and 6 times
3 times and 7 times
3 times and 8 times
3 times and 9 times
4 and 8 times
4 and 6 times
4 and 7 times
49
56
57
58
59
67
68
69
78
79
8948
49
56
57
58
59
67
68
69
78
79
89
4회 및 9회
5회 및 6회
5회 및 7회
5회 및 8회
5회 및 9회
6회 및 7회
6회 및 8회
6회 및 9회
7회 및 8회
7회 및 9회
8회 및 9회4 and 8 times
4 and 9 times
5 and 6 times
5 and 7 times
5 and 8 times
5 and 9 times
6 and 7 times
6 and 8 times
6 and 9 times
7 and 8 times
7 and 9 times
8 and 9 times
상기 각 실험군의 방법으로 고압 및 상압에서 증숙하는 것을 제외하고는, 상기 실시예 1의 방법으로 총 36개의 흑삼 및 각각의 흑삼추출물을 제조하고, 상기 각각의 흑삼추출물에 포함된 Rg3, Rh2 및 벤조피렌의 함량을 측정하였다(참조: 표 7a 내지 표 7c).Except for steaming at high pressure and normal pressure by the method of each experimental group, a total of 36 black ginseng and each black ginseng extract was prepared by the method of Example 1, and Rg3, Rh2 and benzopyrene contained in the respective black ginseng extracts Was measured (see Tables 7a to 7c).
13
14
15
16
17
18
19
23
24
25
2612
13
14
15
16
17
18
19
23
24
25
26
15.53
15.78
17.43
26.41
24.20
23.11
21.43
13.67
13.92
14.94
24.5714.55
15.53
15.78
17.43
26.41
24.20
23.11
21.43
13.67
13.92
14.94
24.57
28
29
34
35
36
37
38
39
45
46
4727
28
29
34
35
36
37
38
39
45
46
47
22.87
21.33
12.42
13.51
23.87
22.67
21.37
20.34
12.37
22.40
21.0423.69
22.87
21.33
12.42
13.51
23.87
22.67
21.37
20.34
12.37
22.40
21.04
49
56
57
58
59
67
68
69
78
79
8948
49
56
57
58
59
67
68
69
78
79
89
18.41
21.69
20.38
18.22
16.44
18.54
15.17
14.67
13.87
13.24
12.1119.96
18.41
21.69
20.38
18.22
16.44
18.54
15.17
14.67
13.87
13.24
12.11
상기 표 7a에서 보듯이, 제 1회 및 제 6회에 고압으로 증숙한 경우(실험군 16), Rg3의 함량이 가장 우수함을 알 수 있었다.As shown in Table 7a, when steamed at high pressure in the first and sixth times (Experimental group 16), it was found that the content of Rg3 is the best.
13
14
15
16
17
18
19
23
24
25
2612
13
14
15
16
17
18
19
23
24
25
26
25.34
27.94
29.35
45.47
43.28
41.22
39.17
24.28
26.32
28.47
42.7023.40
25.34
27.94
29.35
45.47
43.28
41.22
39.17
24.28
26.32
28.47
42.70
28
29
34
35
36
37
38
39
45
46
4727
28
29
34
35
36
37
38
39
45
46
47
40.06
37.34
25.18
27.55
40.53
39.98
38.67
35.29
26.14
39.67
38.4241.32
40.06
37.34
25.18
27.55
40.53
39.98
38.67
35.29
26.14
39.67
38.42
49
56
57
58
59
67
68
69
78
79
8948
49
56
57
58
59
67
68
69
78
79
89
33.18
37.94
37.08
34.20
30.87
35.74
32.64
38.64
30.87
36.50
33.2436.41
33.18
37.94
37.08
34.20
30.87
35.74
32.64
38.64
30.87
36.50
33.24
상기 표 7b에서 보듯이, 제 1회 및 제 6회에 고압으로 증숙한 경우(실험군 16), Rh2의 함량이 가장 우수함을 알 수 있었다.As shown in Table 7b, when steamed at high pressure in the first and sixth times (Experimental group 16), it was found that the content of Rh2 is the best.
13
14
15
16
17
18
19
23
24
25
2612
13
14
15
16
17
18
19
23
24
25
26
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.01.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
28
29
34
35
36
37
38
39
45
46
4727
28
29
34
35
36
37
38
39
45
46
47
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.01.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
49
56
57
58
59
67
68
69
78
79
8948
49
56
57
58
59
67
68
69
78
79
89
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.01.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
상기 표 7c에서 보듯이, 모든 경우에서 벤조피렌의 함량은 변화되지 않았다.As shown in Table 7c, the content of benzopyrene did not change in all cases.
결국, 표 7a 내지 표 7c의 결과를 종합하면, 제 1회 및 제 6회에 고압으로 증숙한 경우(실험군 16)에 Rg3와 Rh2의 함량이 가장 우수하고, 벤조피렌의 함량이 증가되지도 않음을 확인하였는 바, 제 1회 및 제 6회에 고압으로 증숙하고, 나머지는 상압으로 증숙할 경우에 Rg3 및 Rh2의 함량을 극대화한 흑삼을 제조할 수 있음을 알 수 있었다.As a result, when the results of Tables 7a to 7c are summarized, the contents of Rg3 and Rh2 are the best in the case of high-pressure steaming in the first and sixth times (Experimental group 16), and the content of benzopyrene does not increase. As a result, it was found that black ginseng maximizing the contents of Rg3 and Rh2 could be produced when steaming at high pressure in the first and sixth times and steaming the rest at normal pressure.
실시예 4: 흑삼의 항암효과 Example 4 Anticancer Effect of Black Ginseng
본 발명의 방법으로 제조된 흑삼 및 흑삼 추출물이 종래의 방법으로 제조된 흑삼 및 흑삼 추출물보다 상대적으로 우수한 항암활성을 나타내는지를 확인하기 위하여, 본 발명의 방법으로 제조된 흑삼과 종래의 방법으로 제조된 흑삼으로부터 각각의 흑삼 추출물을 수득하고, 이를 폐암세포에 처리하여 각각의 항암활성을 비교하였다.In order to confirm whether the black ginseng and black ginseng extract prepared by the method of the present invention show relatively superior anticancer activity than the black ginseng and black ginseng extract prepared by the conventional method, the black ginseng prepared by the method of the present invention and the conventional method Each black ginseng extract was obtained from black ginseng and treated to lung cancer cells to compare their anticancer activity.
실시예 4-1: 흑삼 및 흑삼 추출물의 수득 Example 4-1 : Obtaining Black Ginseng and Black Ginseng Extract
금산에서 생산되어 유통되는 5년근 수삼을 구입한 후, 스크류 세척기에 넣고 10분간 총 3회 반복해서 세척하고, 증숙시에 수삼이 손상되는 것을 방지하기 위하여, 40℃에서 24시간동안 방치하여 건조시켰다. 이어, 증숙기에 넣고 100℃에서 2시간동안 증숙시키고, 60℃에서 2시간 동안 건조시키는 공정을 9회 반복하여 흑삼을 제조하였다. 이때, 제 1회 및 제 6회차 증숙공정은 10기압의 압력하에서 수행하였다.After purchasing 5-year-old ginseng produced and distributed in Geumsan, it was put in a screw washer and washed three times for a total of 10 minutes. In order to prevent the fresh ginseng from being damaged during steaming, it was left to dry at 40 ° C. for 24 hours. . Subsequently, it was put into a steamer and steamed at 100 ° C. for 2 hours, and dried at 60 ° C. for 2 hours to prepare black ginseng nine times. At this time, the first and sixth steaming process was performed under a pressure of 10 atm.
상기 채취한 각 시료 100g을 마쇄하고, 이에 500㎖의 물을 가하여 실온에서 5시간동안 방치한 다음, 메탄올 5L를 가하여 60℃에서 4시간 동안 추출하고, 이를 여과한 다음, 감압농축기에 적용하여 농축하고, 동결건조하여 고체상의 흑삼 추출물(실험군)을 각각 수득하였다. 100 g of each sample was crushed, and 500 ml of water was added thereto, and the mixture was left at room temperature for 5 hours, 5 L of methanol was added thereto, extracted at 60 ° C. for 4 hours, filtered, and concentrated by applying to a vacuum concentrator. And lyophilized to obtain a solid black ginseng extract (test group), respectively.
한편, 상기 40℃에서 24시간동안 방치하여 건조시킨 인삼을 증숙기에 넣고 상압 및 100℃에서 2시간동안 증숙한 다음, 60℃에서 2시간 동안 건조시키는 공정을 9회 반복하여 종래의 흑삼을 제조하고, 이를 상술한 바와 동일한 방법으로 추출하여, 고체상의 흑삼 추출물(비교실험군)을 수득하였다.On the other hand, the ginseng was left to dry at 40 ℃ for 24 hours in a steamer, steamed for 2 hours at 100 ℃ and atmospheric pressure, and then dried for 6 hours at 60 ℃ repeated 9 times to prepare a conventional black ginseng Then, this was extracted in the same manner as described above to obtain a solid black ginseng extract (comparative experimental group).
실시예 4-2: 폐암세포주에 대한 흑삼 추출물의 항암효과 Example 4-2 Anticancer Effects of Black Ginseng Extract against Lung Cancer Cell Lines
실험실 조건(in vitro)에서 흑삼 추출물의 항암효과를 확인하기 위하여, 배양된 폐암세포주에 흑삼 추출물을 처리하여, 그의 암 치료효과를 확인하였다.In order to confirm the anticancer effect of black ginseng extract in laboratory conditions, the cultured lung cancer cell line was treated with black ginseng extract, and its cancer treatment effect was confirmed.
먼저, 미합중국 종균협회(American Type Culture Collection, ATCC)로부터 입수한 인간 폐암세포(A549)를 RPMI 배양배지(GIBCO/Invitrogen, USA)(10%(v/v) 우태아 혈청, 100units/ml 페니실린 및 100㎍/ml 스트렙토마이신)에서 6-웰 플레이트의 각 웰당 2.5 X 105개의 세포를 분주하여, 37℃, 5%(v/v) CO2의 조건하에서 24시간 동안 배양하였다.First, human lung cancer cells (A549) obtained from the American Type Culture Collection (ATCC) were prepared using RPMI culture medium (GIBCO / Invitrogen, USA) (10% (v / v) fetal bovine serum, 100 units / ml penicillin and 2.5 × 10 5 cells per well of 6-well plates in 100 μg / ml streptomycin) were aliquoted and incubated for 24 hours under conditions of 37 ° C., 5% (v / v) CO 2 .
그런 다음, 상기 실시예 4-1에서 수득한 각각의 흑삼 추출물이 100mg/ml의 농도로 용해된 상기 각 RPMI 배양배지를 상기 배양된 폐암세포주에 각 웰당 1 내지 10ml씩 가하였다. 5일이 경과한 후, 생존하는 폐암세포수를 계수하고, 계수된 폐암세포수를 최초의 폐암세포수에 대한 비율(생존율)로 환산하여, 상기 생존율을 각 실험군 별로 비교하였다(참조: 표 8). 이때, 대조군으로는 흑삼 추출물이 처리되지 않은 폐암세포주를 사용하였다.Then, each RPMI culture medium in which each black ginseng extract obtained in Example 4-1 was dissolved at a concentration of 100 mg / ml was added to the cultured lung cancer cell line by 1 to 10 ml per well. After 5 days, the number of surviving lung cancer cells was counted, and the counted lung cancer cell numbers were converted into the ratio (survival rate) to the initial lung cancer cell numbers, and the survival rates were compared for each experimental group (see Table 8). ). At this time, lung cancer cell line without black ginseng extract was used as a control.
RPMI 배양배지의 처리량Containing Black Ginseng Extract
Throughput of RPMI Culture Medium
1ml
2ml
3ml
4ml
5ml
6ml
7ml
8ml
9ml
10mlControl (0ml)
1ml
2ml
3 ml
4ml
5ml
6ml
7ml
8ml
9 ml
10 ml
67
63
58
50
38
32
25
21
17
15130
67
63
58
50
38
32
25
21
17
15
71
67
66
63
59
54
50
48
46
42130
71
67
66
63
59
54
50
48
46
42
상기 표 8에서 보듯이, 폐암세포주에 흑삼 추출물을 가하지 않은 경우(대조군)에는 5일이 경과한 후에 폐암세포주의 세포수는 약 30%정도 증가하지만, 본 발명의 흑삼 추출물 또는 종래의 흑삼 추출물을 처리하면 흑삼 추출물의 처리량에 비례하여 폐암세포주의 세포수가 급격하게 감소됨을 확인하였다. 아울러, 본 발명의 흑삼 추출물(실험군) 또는 종래의 흑삼 추출물(비교실험군)을 처리한 폐암세포주의 생존율을 비교하면, 실험군이 비교실험군보다도 폐암세포주의 생존율을 더욱 감소시키고, 흑삼 추출물의 처리량이 증가할수록 실험군이 비교실험군보다도 더욱 현저하게 폐암세포주의 생존율을 감소시킴을 확인할 수 있었다.As shown in Table 8, when the black ginseng extract was not added to the lung cancer cell line (control), after 5 days, the cell number of the lung cancer cell line increased by about 30%, but the black ginseng extract of the present invention or the conventional black ginseng extract When treated, it was confirmed that the cell number of the lung cancer cell line was drastically reduced in proportion to the throughput of the black ginseng extract. In addition, when comparing the survival rate of lung cancer cell lines treated with the black ginseng extract (experimental group) of the present invention or the conventional black ginseng extract (comparison experimental group), the experimental group further reduces the survival rate of lung cancer cell line than the comparison experiment group, the throughput of the black ginseng extract increased The more the experimental group reduced the survival rate of lung cancer cell line significantly more than the comparative group.
이는 본 발명의 흑삼 추출물은 Rg3 및 Rh2의 함량이 종래의 흑삼 추출물에 비하여 증가된 것에 기인하는 것으로 추정하였는 바, 이로부터 본 발명의 흑삼 및 흑삼 추출물은 실험실 조건(in vitro)에서 종래의 흑삼 및 흑삼 추출물보다도 높은 항암활성을 나타냄을 알 수 있었다.The black ginseng extract of the present invention was estimated to be due to the increased content of Rg3 and Rh2 compared to the conventional black ginseng extract, from which the black ginseng and black ginseng extract of the present invention is a conventional black ginseng and in vitro conditions (in vitro) It was found that the anticancer activity was higher than that of the black ginseng extract.
실시예 4-3: 암 세포의 전이에 대한 흑삼 추출물의 항암효과 Example 4-3 Anticancer Effect of Black Ginseng Extract on Metastasis of Cancer Cells
생체조건(in vivo)에서 흑삼 추출물의 항암효과를 확인하기 위하여, 마우스에 전이성 암세포와 흑삼 추출물을 동시에 주입하여, 그의 암 치료효과 및 암 예방효과를 확인하였다.In order to confirm the anticancer effect of black ginseng extract in vivo, metastatic cancer cells and black ginseng extract were injected into the mouse at the same time to confirm its cancer treatment effect and cancer prevention effect.
먼저, 전이성 암세포인 B16 멜라노마 세포를 0.02% EDTA를 사용하여 단세포화시키고, 무혈청 RPMI-1640 배지에 7.5X105/ml의 농도로 조심스럽게 재현탁시켰다. 이어, 상기 B16 멜라노마 세포 현탁액 1ml, 실시예 4-1에서 수득한 실험군 또는 비교실험군의 흑삼 추출물이 100mg/ml의 농도로 용해된 무혈청 RPMI-1640 배지(0.1 내지 1ml) 및 무혈청 RPMI-1640 배지를 혼합하여 총 3ml의 혼합액을 수득한 다음, 이중 500㎕를 C57BL/6 마우스(Charles River, Japan)의 꼬리 정맥에 주사하고, 14일동안 사육하였다. 14일이 경과한 후, 상기 각 마우스들을 죽여 폐를 적출하고, 폐의 표면에 존재하는 멜라노마 콜로니의 개수를 해부현미경을 사용하여 계수하였다(참조: 표 9). 이때, 대조군으로는 흑삼 추출물없이 B16 멜라노마 세포 현탁액만을 주사한 C57BL/6 마우스를 이용하였다.First, B16 melanoma cells, metastatic cancer cells, were unicellularized with 0.02% EDTA and carefully resuspended in serum free RPMI-1640 medium at a concentration of 7.5 × 10 5 / ml. Subsequently, serum-free RPMI-1640 medium (0.1-1 ml) and serum-free RPMI- in which the black ginseng extract of the experimental group or the comparative group obtained in 1 ml of the B16 melanoma cell suspension was dissolved at a concentration of 100 mg / ml. 1640 medium was mixed to obtain a total of 3 ml of the mixed solution, and 500 μl of this was injected into the tail vein of C57BL / 6 mice (Charles River, Japan) and bred for 14 days. After 14 days, each of the mice was killed to remove the lungs, and the number of melanoma colonies present on the surface of the lungs was counted using an anatomical microscope (see Table 9). At this time, C57BL / 6 mice injected with only B16 melanoma cell suspension without black ginseng extract were used as a control.
1ml
2ml
3ml
4ml
5ml
6ml
7ml
8ml
9ml
10mlControl (0ml)
1ml
2ml
3 ml
4ml
5ml
6ml
7ml
8ml
9 ml
10 ml
137 ± 28
123 ± 25
118 ± 23
100 ± 21
88 ± 18
62 ± 13
55 ± 11
41 ± 8
37 ± 6
25 ± 2144 ± 40
137 ± 28
123 ± 25
118 ± 23
100 ± 21
88 ± 18
62 ± 13
55 ± 11
41 ± 8
37 ± 6
25 ± 2
139 ± 31
130 ± 27
121 ± 25
112 ± 23
103 ± 19
94 ± 18
85 ± 15
76 ± 12
67 ± 8
55 ± 4144 ± 40
139 ± 31
130 ± 27
121 ± 25
112 ± 23
103 ± 19
94 ± 18
85 ± 15
76 ± 12
67 ± 8
55 ± 4
상기 표 9에서 보듯이, 흑삼 추출물없이 B16 멜라노마 세포 현탁액만을 주사한 경우(대조군)에는 14일이 경과한 후에 폐 멜라노마 콜로니의 수가 약 144개로 계수되었으나, 본 발명의 흑삼 추출물(실험군) 또는 종래의 흑삼 추출물(비교실험군)을 B16 멜라노마 세포 현탁액과 함께 주사하면 주사된 흑삼 추출물의 양에 비례하여 폐 멜라노마 콜로니의 수가 감소되었으므로, 흑삼 추출물은 암 치료효과 뿐만 아니라 암 예방효과까지도 나타냄을 확인하였다. 아울러, 본 발명의 흑삼 추출물(실험군)과 종래의 흑삼 추출물(비교실험군)을 주사한 마우스에서 폐 멜라노마 콜로니의 수를 비교하면, 실험군이 비교실험군보다도 폐 멜라노마 콜로니의 수를 더욱 감소시키고, 흑삼 추출물의 처리량이 증가할수록 실험군이 비교실험군보다도 더욱 현저하게 폐 멜라노마 콜로니의 수를 감소시킴을 알 수 있었다.As shown in Table 9, when only the B16 melanoma cell suspension was injected without the black ginseng extract (control), after 14 days, the number of lung melanoma colonies was counted as about 144, but the black ginseng extract of the present invention (experimental group) or Injecting the conventional black ginseng extract (comparative experimental group) with B16 melanoma cell suspension reduced the number of lung melanoma colonies in proportion to the amount of black ginseng extract injected, so the black ginseng extract not only shows cancer treatment but also prevents cancer. Confirmed. In addition, when comparing the number of lung melanoma colonies in the mice injected with the black ginseng extract (experimental group) of the present invention and the conventional black ginseng extract (comparison experimental group), the experimental group further reduces the number of lung melanoma colonies than the comparison experiment group, As the amount of black ginseng extract increased, the experimental group significantly decreased the number of lung melanoma colonies than the comparative group.
이는 본 발명의 흑삼 추출물은 Rg3 및 Rh2의 함량이 종래의 흑삼 추출물에 비하여 증가하여, 외부에서 주사된 B16 멜라노마 세포의 전이활성을 억제하였기 때문인 것으로 추정되었는 바, 이로부터 본 발명의 흑삼 및 흑삼 추출물은 실험실 조건(in vitro) 및 생체조건(in vivo)에서의 암 치료효과 뿐만 아니라, 암 발생 예방효과의 측면에서도, 종래의 흑삼 및 흑삼 추출물보다도 우수함을 알 수 있었다.The black ginseng extract of the present invention was estimated to be due to the increased content of Rg3 and Rh2 compared to the conventional black ginseng extract, inhibiting the metastatic activity of B16 melanoma cells injected from the outside, from this black ginseng and black ginseng of the present invention The extract was found to be superior to the conventional black ginseng and black ginseng extract in terms of cancer prevention effect as well as cancer treatment effect in laboratory conditions (in vitro) and in vivo (in vivo).
실시예 5: 항암 기능건강식품의 제조 Example 5 Preparation of Anticancer Functional Health Foods
본 발명의 흑삼 추출물을 통상의 식품의 제조시 첨가하여, 암질환의 예방 및 개선 효과를 나타내는 다양한 항암 건강기능식품을 다음과 같이 제조하였다.The black ginseng extract of the present invention was added during the preparation of a conventional food, and various anti-cancer health functional foods having a prevention and improvement effect of cancer disease were prepared as follows.
실시예 5-1: 흑삼 추출물의 제조 Example 5-1 Preparation of Black Ginseng Extract
금산에서 생산되어 유통되는 5년근 수삼을 구입한 후, 스크류 세척기에 넣고 10분간 총 3회 반복해서 세척하고, 증숙시에 수삼이 손상되는 것을 방지하기 위하여, 40℃에서 24시간동안 방치하여 건조시켰다. 이어, 증숙기에 넣고 100℃에서 2시간동안 증숙시키고, 60℃에서 2시간 동안 건조시키는 공정을 9회 반복하여 흑삼을 제조하였다. 이때, 제 1회 및 제 6회차 증숙공정은 15기압의 압력하에서 수행하였다.After purchasing 5-year-old ginseng produced and distributed in Geumsan, it was put in a screw washer and washed three times for a total of 10 minutes. In order to prevent the fresh ginseng from being damaged during steaming, it was left to dry at 40 ° C. for 24 hours. . Subsequently, it was put into a steamer and steamed at 100 ° C. for 2 hours, and dried at 60 ° C. for 2 hours to prepare black ginseng nine times. At this time, the first and sixth steaming process was performed under a pressure of 15 atm.
상기 채취한 각 시료 500g을 마쇄하고, 이에 2.5ℓ의 물을 가하여 실온에서 5시간동안 방치한 다음, 메탄올 15ℓ를 가하여 70℃에서 5시간 동안 추출하고, 이를 여과한 다음, 감압농축기에 적용하여 농축하고, 동결건조하여 고체상의 흑삼 추출물을 제조하였다.500 g of each sample was crushed, 2.5 liters of water was added thereto, and the mixture was left at room temperature for 5 hours, 15 liters of methanol was added thereto, extracted at 70 DEG C for 5 hours, filtered, and concentrated under reduced pressure. And lyophilized to prepare a solid black ginseng extract.
실시예 5-2: 항암 국수의 제조 Example 5-2 Preparation of Anticancer Noodles
실시예 5-1에서 수득한 흑삼 추출물 5g, 소맥분 715g, 계란 80g 및 물 200g을 혼합하여 반죽을 제조하고, 통상의 국수 제조방법에 의하여 면대를 제조하여, 항암 국수를 제조하였다.5 g of black ginseng extract obtained in Example 5-1, 715 g of wheat flour, 80 g of eggs, and 200 g of water were mixed to prepare a dough, and a cotton pad was prepared by a conventional noodle manufacturing method to prepare anti-cancer noodles.
실시예 5-3: 항암 비스킷의 제조 Example 5-3 Preparation of Anticancer Biscuits
실시예 5-1에서 수득한 흑삼 추출물 5g, 소맥분 715g, 우유 200g 및 계란 80g을 혼합하여 반죽을 제조하고, 통상의 비스킷 제조방법에 의하여, 항암 비스킷을 제조하였다.5 g of black ginseng extract obtained in Example 5-1, 715 g of wheat flour, 200 g of milk, and 80 g of eggs were mixed to prepare a dough, and an anticancer biscuit was prepared by a conventional biscuit manufacturing method.
실시예 5-4: 항암 음료의 제조 Example 5-4 Preparation of Anticancer Beverage
실시예 5-1에서 수득한 흑삼 추출물 5g, 과일향 10mg, 과일즙 100g, 안식향산 나트륨 10mg 및 물 900ml을 혼합하여, 항암 음료를 제조하였다.5 g of black ginseng extract obtained in Example 5-1, 10 mg of fruit flavor, 100 g of fruit juice, 10 mg of sodium benzoate and 900 ml of water were mixed to prepare an anticancer beverage.
실시예 5-5: 항암 육류용 양념의 제조 Example 5-5 Preparation of Anticancer Meat Seasoning
실시예 5-1에서 수득한 흑삼 추출물 2g, 배즙 100g, 무즙 100g, 고추장 300g, 소량의 소금, 마늘, 고추, 양파 및 생강을 혼합하여, 항암 육류용 양념을 제조하였다.2 g of black ginseng extract obtained in Example 5-1, 100 g of pear juice, 100 g of radish juice, 300 g of red pepper paste, a small amount of salt, garlic, pepper, onion and ginger were mixed to prepare an anti-cancer meat seasoning.
실시예 5-6: 항암 콩나물 무침의 제조 Example 5-6 Preparation of Anticancer Bean Sprouts
실시예 5-1에서 수득한 흑삼 추출물 5g, 고추가루 150g, 소량의 소금, 마늘, 고추, 양파 및 생강을 혼합하여, 콩나물 무침용 양념을 제조하고, 전기 제조된 양념 200g과 콩나물 800g을 혼합하고, 통상의 방법으로, 항암 콩나물 무침을 제조하였다.5 g of black ginseng extract obtained in Example 5-1, 150 g of red pepper powder, a small amount of salt, garlic, pepper, onion and ginger were mixed to prepare a seasoning for bean sprouts, 200 g of the prepared seasoning and 800 g of bean sprouts were mixed. , In a usual manner, to prepare anti-cancer sprouts.
실시예 5-7: 항암 된장찌게의 제조 Example 5-7 Preparation of Anticancer Miso Stew
실시예 5-1에서 수득한 흑삼 추출물 2g, 된장 600g, 소량의 소금, 마늘, 고추, 양파 및 생강을 혼합하여, 물 500ml에 넣고, 통상의 방법으로 조리하여, 항암 된장찌게를 제조하였다.2 g of black ginseng extract obtained in Example 5-1, 600 g of soybean paste, a small amount of salt, garlic, pepper, onion, and ginger were mixed, put into 500 ml of water, and cooked in a conventional manner to prepare an anti-cancer miso crab.
실시예 5-8: 항암 잡곡밥의 제조 Example 5-8 Preparation of Anticancer Multigrain Rice
실시예 5-1에서 수득한 흑삼 추출물 2g, 검정콩 50g, 수수 50g, 좁쌀 50g 및 백미 348g을 혼합하고, 통상의 방법으로 조리하여, 항암 잡곡밥을 제조하였다.2 g of black ginseng extract obtained in Example 5-1, 50 g of black soybean, 50 g of sorghum, 50 g of millet rice, and 348 g of white rice were mixed and cooked in a conventional manner to prepare anticancer grain rice.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090017259A KR101071851B1 (en) | 2009-02-27 | 2009-02-27 | A Process for Preparing an Extract of Black Ginseng with Increased Rg3 and Rh2 Contents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090017259A KR101071851B1 (en) | 2009-02-27 | 2009-02-27 | A Process for Preparing an Extract of Black Ginseng with Increased Rg3 and Rh2 Contents |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100098208A KR20100098208A (en) | 2010-09-06 |
KR101071851B1 true KR101071851B1 (en) | 2011-10-10 |
Family
ID=43005219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090017259A KR101071851B1 (en) | 2009-02-27 | 2009-02-27 | A Process for Preparing an Extract of Black Ginseng with Increased Rg3 and Rh2 Contents |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101071851B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101093680B1 (en) | 2011-11-14 | 2011-12-15 | 유한회사 가피식품 | Method for producing red ginseng extract with enhanced specific ginsenoside contents and red ginseng extract produced by the same method |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101359078B1 (en) * | 2011-03-08 | 2014-02-05 | 이홍식 | Method of processing roots of wild ginseng |
KR101325832B1 (en) * | 2011-07-14 | 2013-11-05 | 고완석 | BLACK GINSENG HAVING EXCEL CONTENT OF GINSENOSIDE Rh2 INGREDIENT AND THE CONCENTRATE OF BLACK GINSENG AND BLACK GINSENG GOODS MANUFACTURED BY THE SAME |
KR101435930B1 (en) * | 2012-11-14 | 2014-09-01 | 주식회사한국야쿠르트 | Method for production of red ginseng extract enhancing ginsenoside Rg3 and use of thereof as ginsenoside Rg3 enriched products |
KR101583050B1 (en) * | 2013-08-27 | 2016-01-21 | 중부대학교 산학협력단 | Preparation method of black ginseng for increasing ginsenoside Rg3 and decreasing benzopyrene, and the product thereof |
KR101898879B1 (en) * | 2014-03-05 | 2018-09-14 | 재단법인 진안홍삼연구소 | A composition comprising the red ginseng extract of postmanufacture for treating or preventing oral squamous cell carcinoma |
KR101681810B1 (en) * | 2014-06-05 | 2016-12-01 | 동국대학교 경주캠퍼스 산학협력단 | Ginseng preparations containing abundant ginsenoside using a beauveria bassiana and method thereof |
KR20200089370A (en) | 2019-01-16 | 2020-07-27 | 신라대학교 산학협력단 | Kochujang comprising sprout ginseng powder as an active ingredient and method for preparing thereof |
KR102192641B1 (en) * | 2019-05-07 | 2020-12-16 | 대한민국 | Pharmaceutical composition for preventing and treating prostate disease or cancer, comprising the compound isolated from black ginseng and black ginseng extract as an active ingredient |
KR102253143B1 (en) * | 2019-05-09 | 2021-05-17 | 대한민국 | Composition for preventing or treating prostate-related disease comprising a complex extract of Black ginseng and Platycodon grandiflorum |
KR102429921B1 (en) * | 2020-04-20 | 2022-08-08 | 대한민국 | Fermented Black Ginseng extract including alcoholic liver injury prevention functional ingredients and method for manufacturing it |
KR102408623B1 (en) * | 2020-04-20 | 2022-06-14 | 대한민국 | Composition for preventing or treating prostatic diseases comprising Black Ginseng extract or Fermented Black Ginseng extract |
KR102407640B1 (en) | 2020-06-03 | 2022-06-13 | 디티아이코리아(주) | apparatus for generating and storing electricity using sunlight |
KR102295116B1 (en) | 2020-10-23 | 2021-08-31 | 주식회사 한빛향료 | Manufacturing method of black ginseng to improve cognitive function and black ginseng manufactured by the method |
KR102526175B1 (en) * | 2021-11-15 | 2023-04-27 | 주식회사 나투어바이오제약 | A method for preparation fermented black ginseng |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100729214B1 (en) | 2006-11-07 | 2007-06-19 | (주)고려바이오홍삼 | Making manufacture of black ginseng |
-
2009
- 2009-02-27 KR KR1020090017259A patent/KR101071851B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100729214B1 (en) | 2006-11-07 | 2007-06-19 | (주)고려바이오홍삼 | Making manufacture of black ginseng |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101093680B1 (en) | 2011-11-14 | 2011-12-15 | 유한회사 가피식품 | Method for producing red ginseng extract with enhanced specific ginsenoside contents and red ginseng extract produced by the same method |
Also Published As
Publication number | Publication date |
---|---|
KR20100098208A (en) | 2010-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101071851B1 (en) | A Process for Preparing an Extract of Black Ginseng with Increased Rg3 and Rh2 Contents | |
AU2020280860B2 (en) | Anti-influenza virus composition, composition for treating respiratory diseases, and anti-aging composition, comprising dark ginseng extract | |
KR20080106077A (en) | A method for preparing novel black-red ginseng and the extract therefrom and the composition comprising the same | |
KR101165248B1 (en) | Pharmaceutical compositions for prevention and treatment of menopausal symptoms or osteoporosis containing the flavan compounds or the pharmaceutically acceptable salts thereof as active ingredient | |
EP1618875B1 (en) | Composition for inhibition or prevention of bone density lowering | |
KR102045903B1 (en) | Composition for improving premenstrual syndrome symptom comprising extract of Chrysanthemum zawadskii | |
KR101625474B1 (en) | Manufacturing method for mass-production of ginsenoside Rh4 | |
KR101704676B1 (en) | A pharmaceutical composition for preventing or treating cervical cancer comprising gypenoside LXXV | |
KR102187335B1 (en) | Composition for improving premenstrual syndrome symptom comprising compounds isolated from Hordeum vulgare extract | |
KR102331317B1 (en) | Composition for improving premenstrual syndrome symptom comprising compounds isolated from Chrysanthemum zawadskii extract | |
EP2792666B1 (en) | Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same | |
KR102002260B1 (en) | A composition comprising the compounds isolated from an extract of Allium sativum L. for treating and preventing muscle-related disorder | |
KR20170109703A (en) | A pharmaceutical composition for preventing or treating cancer comprising fractions of herbal mixture extract | |
KR101338172B1 (en) | Pharmaceutical composition comprising the extract paeonia lactiflora, fraction thereof or compound isolated therefrom as an active ingredient | |
KR101794080B1 (en) | Anti-cancer Composition for Lung Cancer Using of Extracts of the Mixture of Saururus chinensis, Scutellariae Radix, etc. | |
KR101406126B1 (en) | Composition containing Hedyotis diffusa extract for treating or preventing obesity | |
KR101640037B1 (en) | Composition for treating prostate disease comprising extract, fractions or new compounds purified from cornus alba | |
KR101996184B1 (en) | Adjuvant of anti-cancer agent comprising and an extract of Allium sativum L. for treating and preventing cachexia | |
KR102192641B1 (en) | Pharmaceutical composition for preventing and treating prostate disease or cancer, comprising the compound isolated from black ginseng and black ginseng extract as an active ingredient | |
KR102441302B1 (en) | Composition for anti-cancer containing deacetyl torilin as effective component | |
EP4374862A1 (en) | Composition including paeoniflorin for prevention or treatment of cachexia and muscle loss | |
KR101440855B1 (en) | A composition comprising known compounds isolated from the extract of pine tree leaf for the prevention and treatment of cancer diseases | |
KR101965699B1 (en) | A composition comprising and an extract of Allium sativum L. for treating and preventing muscle-related disorder | |
KR102068469B1 (en) | Composition comprising Boehmeria platanifolia extract for treating or preventing cancer | |
WO2013133677A1 (en) | Composition containing reaction mixture of red-ginseng extract and persimmon vinegar for preventing or treating vascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150922 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161005 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20181017 Year of fee payment: 8 |